NCT06540391
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06540391
Title A Phase 1b Trial to Evaluate Safety of MB097 in Combination With Pembrolizumab in Melanoma Patients (MELODY-1)
Acronym MELODY-1
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Microbiotica Ltd
Indications
Therapies
Age Groups: adult | senior
Covered Countries ITA | GBR | FRA | ESP

Facility Status City State Zip Country Details
Centre Georges Francois Leclerc Dijon France Details
CHU de Lille - Hopital Claude Huriez Lille France Details
Centre Leon Berard Lyon France Details
AP-HM - Hopital de la Timone Marseille France Details
HCL Centre Hospitalier Lyon Sud Pierre-Bénite France Details
Istituto Europeo di Oncologia Milan Italy Details
Istituto Nazionale Tumori IRCCS Fondazione G. Pascale Napoli Italy Details
Istituto Clinico Humanitas Rozzano Italy Details
Hospital Universitario 12 de Octubre Madrid Spain Details
Hospital Universitario Ramon y Cajal Madrid Spain Details
South Texas Accelerated Research Therapeutics (START) Madrid - CIOCC Madrid Spain Details
Consorcio Hospital General Universitario de Valencia Valencia Spain Details
Sussex Cancer Centre Brighton United Kingdom Details
Addenbrooke's Hospital Cambridge United Kingdom Details
Beatson West of Scotland Cancer Centre Glasgow United Kingdom Details
The Royal Marsden NHS Foundation Trust London United Kingdom Details
The Christie NHS Foundation Trust Manchester United Kingdom Details
Freeman Hospital Newcastle United Kingdom Details
Royal Marsden Hospital - Surrey Sutton United Kingdom Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field